New cancer drug AB801 enters human safety testing

NCT ID NCT06120075

Ongoing Disease control Sponsor: Arcus Biosciences, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 4 times

Summary

This early-stage study is testing a new drug, AB801, alone or with other treatments, in about 91 people with advanced cancers (like lung, colon, or breast cancer) that have not responded to standard therapies. The main goal is to check the drug's safety and find the best dose for future studies. Participants will be closely monitored for side effects and how the drug moves through the body.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast carcinoma cancer colorectal carcinoma head and neck squamous cell carcinoma non-small cell lung carcinoma ovarian carcinoma renal cell carcinoma urinary bladder carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED CANCER

Contacts and locations

Locations

Research Site

Denver, Colorado, 80218, United States
Research Site

Washington D.C., District of Columbia, 20007, United States
Research Site

Atlanta, Georgia, 30322, United States
Research Site

Grand Rapids, Michigan, 49546, United States
Research Site

New York, New York, 10128, United States
Research Site

Philadelphia, Pennsylvania, 19104, United States
Research Site

Dallas, Texas, 75230, United States
Research Site

San Antonio, Texas, 78229, United States
Research Site

West Valley City, Utah, 84119, United States
Research Site

Fairfax, Virginia, 22031, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.